Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen D Smith

Showing results (101-110 of 159) with videos related to

Pageof 16
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2017
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell LymphomaYolanda D Tseng, Philip A Stevenson, Ryan D Cassaday, et al.
Leukemia & Lymphoma|August 13, 2009
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphomaStephen D Smith, Brian J Bolwell, Anjali S Advani, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 24, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell LymphomaCarrie Ho, Neena Kennedy, Mengyang Di, et al.
British Journal of Haematology|January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphomaAndrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.
JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.
American Journal of Hematology|January 22, 2019
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCLStephen D Smith, Prathima Reddy, Alexandra Sokolova, et al.
Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Blood Advances|October 14, 2021
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphomaVictor A Chow, Ryan D Cassaday, Theodore A Gooley, et al.
Pageof 16

Showing results (101-110 of 159) with videos related to

Sort By:
Pageof 16
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 25, 2017
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell LymphomaYolanda D Tseng, Philip A Stevenson, Ryan D Cassaday, et al.
Leukemia & Lymphoma|August 13, 2009
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphomaStephen D Smith, Brian J Bolwell, Anjali S Advani, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 24, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell LymphomaCarrie Ho, Neena Kennedy, Mengyang Di, et al.
British Journal of Haematology|January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphomaAndrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell LymphomaSolomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.
JCO Oncology Practice|November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World ExperienceIvan J Huang, Grace T Baek, Jonathan Cohen, et al.
American Journal of Hematology|January 22, 2019
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCLStephen D Smith, Prathima Reddy, Alexandra Sokolova, et al.
Practical Radiation Oncology|October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell LymphomaAileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Blood Advances|October 14, 2021
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphomaVictor A Chow, Ryan D Cassaday, Theodore A Gooley, et al.
Pageof 16